# Lazcluze (lazertinib mesylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lazertinib

> The FDA approved Lazcluze (lazertinib mesylate), sponsored by JOHNSON & JOHNSON (JNJ), on August 19, 2024 for to treat non-small cell lung cancer.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Lazcluze (lazertinib mesylate) FDA approved?

Yes. The FDA approved Lazcluze (lazertinib mesylate), sponsored by JOHNSON & JOHNSON (JNJ), on August 19, 2024 for to treat non-small cell lung cancer. FDA novel drug approvals: "Lazcluze | lazertinib | 8/19/2024 | To treat non-small cell lung cancerDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/lazertinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/lazertinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Lazcluze (lazertinib mesylate) |
| Codes | JNJ-73841937 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | To treat non-small cell lung cancer, [Carcinoma, Non-small-Cell Lung](https://sec-api.dev/indications/carcinoma-non-small-cell-lung) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### August 19, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat non-small cell lung cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Lazcluze | lazertinib | 8/19/2024 | To treat non-small cell lung cancerDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA219008 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240819, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product LAZCLUZE (LAZERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219008%22

### August 14, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA219008 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250814, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product LAZCLUZE (LAZERTINIB MESYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219008%22

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06120140

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06120140 (Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06120140

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Carcinoma, Non-small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05498428

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Carcinoma, Non-small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05498428 (A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-17 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT05498428

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07586202

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07586202 (A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-02 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07586202

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06667076 (A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06667076

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Carcinoma, Non-Small-Cell Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06667076 (A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-23 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06667076

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05), [August 2027](https://sec-api.dev/fda-calendar/2027-08), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lazertinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lazcluze (lazertinib mesylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lazertinib

```bibtex
@misc{secapidev_pdufa_lazertinib_20261116,
  title        = {Lazcluze (lazertinib mesylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lazertinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lazertinib_20261116","title":"Lazcluze (lazertinib mesylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lazertinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
